Overview

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Terminated

Trial end date:
2019-09-17

Target enrollment:

Participant gender:

Summary

This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC

Phase:

Phase 1

Details

Lead Sponsor:

Pellficure Pharmaceuticals, Inc

Treatments:

Androgens